SBI Securities’s Co-Diagnostics CODX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$251 Buy
81
+23
+40% +$71 ﹤0.01% 3259
2026
Q1
$108 Buy
58
+11
+23% +$38 ﹤0.01% 3383
2025
Q4
$236 Hold
47
﹤0.01% 3158
2025
Q3
$481 Hold
47
﹤0.01% 2984
2025
Q2
$391 Hold
47
﹤0.01% 3065
2025
Q1
$433 Buy
47
+7
+18% +$134 ﹤0.01% 2920
2024
Q4
$898 Buy
+40
New +$1.26K ﹤0.01% 2659

SBI Securities's CODX Position: Q2 2026 in Review

SBI Securities increased its Co-Diagnostics (CODX) stake by 40% in Q2 2026, buying an estimated $71 and bringing the position to 81 shares worth $251. The position accounts for ﹤0.01% of the portfolio, ranked #3259.

SBI Securities first reported a position in CODX in Q4 2024 and has held it in 7 quarters since. The position peaked at $898 in Q4 2024. 1 fund tracked by Wall St. Rank holds CODX as of Q2 2026.

  • SBI Securities held 81 shares of Co-Diagnostics worth $251 as of Q2 2026.
  • SBI Securities bought 23 Co-Diagnostics shares in Q2 2026, an estimated $71.
  • Co-Diagnostics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3259 holding.
  • SBI Securities first reported a position in Co-Diagnostics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Co-Diagnostics position peaked at $898 in Q4 2024.
  • 1 fund tracked by Wall St. Rank held Co-Diagnostics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.